CD4 and COVID-19: found that CD4+/CD8+ T cells from convalescent COVID-19 patients and vaccine recipients had similar cross-reactivity towards the Alpha, Beta, Gamma, and Epsilon variants—with a reduction in cross-reactivity among the variants of 10-22% (198).